Bladder cancer is a heterogenous neoplasm that ranges from non-life-threatening, low-grade, superficial papillary lesions to high-grade invasive tumors that often metastasizes at the presentation.

It is the most common cancer involving the urinary system and it is the 11th most commonly diagnosed in the world.

Microscopic or gross painless hematuria is the most common presenting complaint.


  • Alternative treatment in patients unfit for or opposed to radical surgery or for local palliative treatment inpatients with metastatic disease
  • Preoperative RT prior to cystectomy may be considered in patients with invasive tumors 
  • May consider adjuvant pelvic irradiation for patients with pT3/pT4 pN0-2 disease who recently underwent radical cystectomy with ileal conduit
  • Intraoperative RT may be considered in patients with tumors extending to the abdominal and/or pelvic wall 
  • Palliative RT combined with radiosensitizing chemotherapy is recommended especially for patients with metastasis or disease recurrence
  • Recommended dose: 1.8-2.0 Gy daily fractionation
    • Conventional or accelerated hyperfractionation of 39.6–50.4 Gy may be applied to the whole bladder with or without pelvic nodal irradiation
  • Absence of hydronephrosis and extensive carcinoma in situ is a factor for positive treatment response


  • For muscle-invasive bladder cancer, radical radiotherapy is given using a radiosensitiser (eg Mitomycin + Fluorouracil or Cisplatin plus Fluorouracil or Cisplatin plus Paclitaxel or Cisplatin alone)
    • Low-dose Gemcitabine may also be considered
  • Conventional fractional radiation therapy with a radiosensitizer may be used as palliative therapy in patients with advanced or metastatic disease
    • Recommended regimens include Cisplatin (preferred), taxanes (Docetaxel, Paclitaxel), Fluorouracil monotherapy, Fluorouracil + Mitomycin, low-dose Gemcitabine, or Capecitabine monotherapy
  • Concurrent chemoradiotherapy is an alternative option to radical cystectomy in patients with recurrent Ta-T1 disease (without extensive Tis) with history of BCG therapy and ineligible for cystectomy
    • Also recommended for patients in need of added tumor cytotoxicity
Editor's Recommendations
Most Read Articles
2 days ago
While early-phase clinical trials may demonstrate substantial levels of overall response rates in patients with relapsed/refractory multiple myeloma (RRMM), high heterogeneity of evidence prevents the accurate assessment of clinical benefit before patient participation, reports a recent meta-analysis.
Elvira Manzano, 28 Mar 2021
The COVID-19 vaccine AZD1222 by AstraZeneca and the University of Oxford was 79 percent effective overall in preventing symptomatic infections – higher than observed in previous clinical trials of the vaccine – at the interim analysis of a US phase III trial.
2 days ago
The chances of a live birth following either fresh or frozen-thawed embryo transfer cycles cannot be predicted by endometrial thickness alone, according to a study.
01 Apr 2021
Migraine and headache are common ailments of people living in the modern era. Dr Jon Marshall of The Singapore Headache and Migraine Clinic shares his insights with Pearl Toh on how to manage migraine and headache using non-pharmaceutical strategies, with a focus on the manual medicine approach.